期刊文献+

组织固定和处理对免疫组织化学染色结果的影响及其标准化探讨 被引量:14

原文传递
导出
摘要 免疫组织化学(immunohistochemistry,IHC)作为诊断和指导治疗的重要工具,目前已在外科病理学中广泛运用。随着HER2、ER、PR等一些重要治疗和预后预测指标的运用,IHC的检测标准化问题已日益凸显。尽管目前试剂质量和自动化程度有大幅度的提高,但IHC结果的不稳定情况仍相当突出。影响IHC染色结果的几个主要因素包括组织固定和处理、抗原修复、抗体质量、检测系统等。
出处 《中华病理学杂志》 CAS CSCD 北大核心 2009年第12期852-855,共4页 Chinese Journal of Pathology
  • 相关文献

参考文献25

  • 1Wemer M, Chott A, Fabiano A, et al. Effect of formalin tissue fixation and processing on immunohistochemistry. Am J Surg Pathol, 2000, 24(7):1016-1019.
  • 2von Wasielewski R, Mengel M, Nolte M, et al. Influence of fixation, antibody clones and signal amplification on steroid receptor analysis [ J/OL ]. Breast J, ( 2003-1 ) [ 2009-10 ]. http:// www3. interscience, wiley. com/journal/119133145/abstract.
  • 3Oyama T, Ishikawa Y, Hayashi M, et al. The effects of fixation, processing and evaluation criteria on immunohistochemical detection of hormone receptors in breast cancer. Breast Cancer, 2007,14(2) :182-188.
  • 4Khoury T, Sait S, Hwang H, et al. Delayed formalin fixation effect on breast biomarkers [ J/OL]. Mod Pathol, (2009-9) [ 2009- 10]. http ://www. nature, com/modpathol/journal/vaop/ncurrent/ abs/modpathol2009117 a.
  • 5Douglas-Jones AG, CoUett N, Morgan JM, et al. Comparison of core oestrogen receptor (ER) assay with excised tumour: intratumoral distribution of ER in breast carcinoma. J Clin Pathol, 2001,54(12) :951-955.
  • 6Helander KG. Kinetic studies of formaldehyde binding in tissue. Biotech Histochem, 1994,69 ( 3 ) : 177-179.
  • 7Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Human Epidermal Growth Factor Receptor 2 testing in breast cancer. Arch Pathol Lab Med, 2007,131 ( 1 ) :18- 43.
  • 8Fox CH, Johnson FB, Whiting J, et al. Formaldehyde fixation. J Histochem Cytochem, 1985,33 (8) :845-853.
  • 9Buesa RJ. Histology without formalin? Ann Diagn Pathol, 2008, 12(6) :387-396.
  • 10Mitchell D, Ibrahim S, Gusterson BA. Improved immunohistochemical localization of tissue antigens using modified methacarn fixation. J Histochem Cytochem, 1985,33 ( 5 ) : 491- 495.

二级参考文献10

  • 1Watters AD,Going JJ,Cooke GT,et al.Chromosome 17 aneusomy is associated with poor prognostic factors in invesive breast carcinoma.Breast Cancer Res Treat,2003,77:109-114.
  • 2Bilous M,Morey A,Armes J,et al.Chromogenic in situ hybridisation testing for HER2 gene amplification in breast cancer produces highly reproducible results concordant with fluorescence in situ hybridisation and immunohistochemistry.Pathology,2006,38:120-124.
  • 3Goldhirsch A,Glick JH,Gelber RD,et al.Meeting highlights:international expert consensus on the primary therapy of early breast cancer 2005.Annals Oncol,2005,16:1569-1583.
  • 4The Center For Devices and Radiological Health (CDRH) of the Food and Drug Administration.A document of evaluation about the PathVysionTM HER-2 DNA Probe Kit of Vysis,INC.for detecting amplification of the HER-2/neu gene via fluorescence in situ hybridization (FISH) in formalin-fixed,paraffin-embedded human breast cancer tissue specimens.[2001-12-31].http://www.fda.gov/cdrh/pmapage.html.
  • 5Shak S.Overview of the trastuzumab (Hereeptin) anti-HER2monoclonal antibody clinical program in HER2-overexpressing metastatic breast cancer.Herceptin Multinational Investigator Study Group.Semin Oncol,1999,26(4 Suppl 12):71-77.
  • 6Hammock L,Lewis M,Philips,C,et al.Strong HER-2/neu protein overexpression by immunohistochemistry often does not predict oncogene amplification by fluorescence in situ hybridization.Hum Pathol,2003,34:1043-1047.
  • 7北京市发展和改革委员会.关于公布荧光原位杂交基因检测(FISH)等新增医疗服务价格项目的通知.京发改[2006]1376号.http://www.bjpc.gov.cn/tztg/200608/t129145.btm.
  • 8Hicks DG,Tubbs RR.Assessment of the Her2 status in breast cancer by fluorescence in situ hybridization:a technical review with interpretive guidelines.Hum Pathol,2005,36:250-261.
  • 9Wang S,Hossein Saboorian H,Frenkel EP,et al.Aneusomy 17 in breast cancer:its role in HER-2/neu protein expression and implication for clinical assessment of HER-2/neu status.Mod Pathol,2002,15:137-145.
  • 10Risio M,Casorzo L,Redana S,et al.HER2 gene-amplified breast cancers with monosomy of chromosome 17 are poorly responsive to trastuzumab-based treatment.Oncol Rep,2005,13:305-309.

共引文献163

同被引文献87

引证文献14

二级引证文献65

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部